Sign In to Follow Application
View All Documents & Correspondence

Pharmaceutical Formulations

Abstract: Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
07 September 2022
Publication Number
37/2022
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
NNCP-IN@novonordisk.com
Parent Application
Patent Number
Legal Status
Grant Date
2024-05-27
Renewal Date

Applicants

NOVO NORDISK A/S
Novo Allé 2880 Bagsværd

Inventors

1. SANDER, Tommy
Novo Allé 2880 Bagsværd
2. POULSEN, Christian
Novo Allé 2880 Bagsværd
3. HANSEN, Rosa, Rebecca, Erritzøe
Novo Allé 2880 Bagsværd

Specification

Documents

Application Documents

# Name Date
1 202247051055.pdf 2022-09-07
2 202247051055-STATEMENT OF UNDERTAKING (FORM 3) [07-09-2022(online)].pdf 2022-09-07
3 202247051055-PRIORITY DOCUMENTS [07-09-2022(online)].pdf 2022-09-07
4 202247051055-POWER OF AUTHORITY [07-09-2022(online)].pdf 2022-09-07
5 202247051055-FORM 1 [07-09-2022(online)].pdf 2022-09-07
6 202247051055-DRAWINGS [07-09-2022(online)].pdf 2022-09-07
7 202247051055-DECLARATION OF INVENTORSHIP (FORM 5) [07-09-2022(online)].pdf 2022-09-07
8 202247051055-COMPLETE SPECIFICATION [07-09-2022(online)].pdf 2022-09-07
9 202247051055-FORM 18 [27-10-2022(online)].pdf 2022-10-27
10 202247051055-FORM-26 [12-01-2023(online)].pdf 2023-01-12
11 202247051055-Proof of Right [17-02-2023(online)].pdf 2023-02-17
12 202247051055-FER.pdf 2023-03-01
13 202247051055-Information under section 8(2) [06-03-2023(online)].pdf 2023-03-06
14 202247051055-FORM 3 [06-03-2023(online)].pdf 2023-03-06
15 202247051055-FORM 4(ii) [25-08-2023(online)].pdf 2023-08-25
16 202247051055-Information under section 8(2) [05-09-2023(online)].pdf 2023-09-05
17 202247051055-FORM 3 [05-09-2023(online)].pdf 2023-09-05
18 202247051055-FORM-26 [25-10-2023(online)].pdf 2023-10-25
19 202247051055-OTHERS [30-11-2023(online)].pdf 2023-11-30
20 202247051055-FER_SER_REPLY [30-11-2023(online)].pdf 2023-11-30
21 202247051055-CLAIMS [30-11-2023(online)].pdf 2023-11-30
22 202247051055-US(14)-HearingNotice-(HearingDate-15-03-2024).pdf 2024-03-01
23 202247051055-Information under section 8(2) [05-03-2024(online)].pdf 2024-03-05
24 202247051055-FORM 3 [05-03-2024(online)].pdf 2024-03-05
25 202247051055-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [08-03-2024(online)].pdf 2024-03-08
26 202247051055-US(14)-ExtendedHearingNotice-(HearingDate-12-04-2024).pdf 2024-03-15
27 202247051055-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [08-04-2024(online)].pdf 2024-04-08
28 202247051055-US(14)-ExtendedHearingNotice-(HearingDate-10-05-2024).pdf 2024-04-12
29 202247051055-Correspondence to notify the Controller [07-05-2024(online)].pdf 2024-05-07
30 202247051055-Written submissions and relevant documents [24-05-2024(online)].pdf 2024-05-24
31 202247051055-Annexure [24-05-2024(online)].pdf 2024-05-24
32 202247051055-PatentCertificate27-05-2024.pdf 2024-05-27
33 202247051055-IntimationOfGrant27-05-2024.pdf 2024-05-27
34 202247051055-CERTIFIED COPIES-CERTIFICATE U-S 72 147 & UR 133-2 [14-04-2025(online)].pdf 2025-04-14
35 202247051055-CERTIFIED COPIES-CERTIFICATE U-S 72 147 & UR 133-2 [14-07-2025(online)].pdf 2025-07-14
36 202247051055-FORM-26 [24-07-2025(online)].pdf 2025-07-24

Search Strategy

1 searchstrategy202247051055E_24-02-2023.pdf

ERegister / Renewals

3rd: 09 Aug 2024

From 17/02/2023 - To 17/02/2024

4th: 09 Aug 2024

From 17/02/2024 - To 17/02/2025

5th: 13 Feb 2025

From 17/02/2025 - To 17/02/2026